Valuation: Aquestive Therapeutics, Inc.

Market Cap 531M 476M 440M 399M 745M 50.56B 754M 5.27B 2.1B 26.46B 1.99B 1.95B 84B P/E 2026 *
-8.4x
P/E 2027 * -8.81x
Enterprise Value 453M 406M 376M 340M 636M 43.14B 643M 4.49B 1.79B 22.57B 1.7B 1.66B 71.66B EV / Sales 2026 *
8.87x
EV / Sales 2027 * 7.83x
Free-Float
89.21%
Yield 2026 *
-
Yield 2027 * -
1 day+3.93%
1 week+3.68%
Current month-8.64%
1 month-10.95%
3 months+12.50%
6 months+3.42%
Current year-34.52%
1 week 3.92
Extreme 3.92
4.23
1 month 3.65
Extreme 3.65
4.98
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
6.92
3 years 1.41
Extreme 1.4052
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
15/10/26 Sell

Chief Executive Officer

-25,000 0.0199%
15/10/26 Other

Director

0 0% -
15/9/26 Sell

Chief Executive Officer

-25,000 0.0199%
Change 5-day change 1-year change 3-year change Capi.($)
+3.93%+3.68%-37.05%+197.89% 531M
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+0.34%+1.84%+30.70%+54.27% 294B
-0.45%+1.19%+2.89%+26.08% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.53%+1.62%+32.87%+88.55% 403.77B
Weighted average by Cap. +0.26%+1.50%+44.51%+89.12%

Financials

2026 *2027 *
Net sales 51.04M 45.79M 42.34M 38.34M 71.64M 4.86B 72.5M 506M 202M 2.54B 192M 187M 8.08B 67.77M 60.8M 56.21M 50.91M 95.12M 6.45B 96.27M 672M 268M 3.38B 254M 249M 10.72B
Net income -62.87M -56.41M -52.15M -47.23M -88.24M -5.99B -89.31M -624M -248M -3.13B -236M -231M -9.95B -60.23M -54.04M -49.96M -45.25M -84.53M -5.74B -85.55M -597M -238M -3B -226M -221M -9.53B
Net Debt -78M -69.98M -64.7M -58.6M -109M -7.43B -111M -774M -308M -3.89B -293M -287M -12.34B -
Projected Income Statement - Annual - Aquestive Therapeutics, Inc.
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
28/10/26 USD 4.230 +3.93% 1,551,745
27/10/26 USD 4.070 +2.52% 1,325,306
26/10/26 USD 3.970 -0.75% 1,273,417
23/10/26 USD 4.000 -3.15% 1,746,678
22/10/26 USD 4.130 +1.23% 1,853,118
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Aquestive Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.230USD
Average target price
9.333USD
Spread / Average Target
+120.65%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Aquestive Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. AQST Stock